ALXN stock news

Is (ALXN) Outperforming Other Medical Stocks This Year? Read more
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Read more
Alexion (ALXN) stock may be a good choice for value-oriented investors right now from multiple angles. Read more
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials. Read more
Alexion Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon. Read more
Drugmakers GlaxoSmithKline and Alexion Pharmaceuticals topped sales and adjusted earnings estimates Wednesday, though Alexion stock slipped as one rare-disease drug cannibalized another. Read more
Alexion (ALXN) delivered earnings and revenue surprises of 11.86% and 2.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results. Read more
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Read more
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). Read more
These are the stocks posting the largest moves in the premarket. Read more

5 Stocks To Watch For July 5, 2019

04:19am, Friday, 05'th Jul 2019
Some of the stocks that may grab investor focus today are: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) disclosed that ULTOMIRIS has received marketing … Read more
Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults. Read more
Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder. Read more
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase. Read more

Proudly made at